Ovitrelle 250 micrograms/0.5 ml pre-filled pen | SPC

What Ovitrelle is

Ovitrelle 250 micrograms/0.5 ml pre-filled pen contains choriogonadotropin alfa. It is used in fertility treatment settings where a healthcare professional has decided that an ovulation trigger is appropriate.

The pre-filled pen is designed for subcutaneous injection. The exact timing and use depend on the wider treatment plan, so patients should follow the instructions given by their fertility team.

According to the current product information provided in the source content, Ovitrelle is manufactured by Merck Serono.

How Ovitrelle is used

Ovitrelle is given as an injection under the skin. The pen format is intended to make administration more straightforward, but the injection should still be used exactly as instructed.

• Use only the dose and timing prescribed by the healthcare team.
• Check that the solution looks suitable before use, following the leaflet instructions.
• Wash hands before handling the pen.
• Rotate injection sites if advised to do so.
• Ask a pharmacist or nurse to show the correct technique if needed.

In fertility treatment, timing can be important. Patients should confirm when the injection should be given in relation to other medicines and monitoring appointments.

Who should not use it

The source content lists several situations where Ovitrelle should not be used. These include:

• Known hypersensitivity to choriogonadotropin alfa or any excipient.
• Ovarian cysts or enlarged ovaries.
• Ovarian Hyperstimulation Syndrome (OHSS).
• Uterine bleeding of unknown origin.
• Uncontrolled thyroid or adrenal disorders.
• Pregnancy or suspected pregnancy.

If any of these apply, the official leaflet and a healthcare professional should be consulted before use.

Precautions and monitoring

Fertility treatment with Ovitrelle may involve monitoring. The source content notes that blood tests may be used to follow treatment progress and hormone levels.

Patients should be alert for possible signs of OHSS, which can include abdominal pain, bloating, or changes in weight. Any concerning symptoms should be discussed with a healthcare professional promptly.

It is also important to share a full medical history with the fertility team, especially if there are other health conditions or if other fertility medicines are being used.

Possible side effects

Like all medicines, Ovitrelle may cause side effects, although not everyone will experience them.

• Commonly reported effects: injection site reactions such as redness, swelling, or pain.
• Other effects mentioned in the source content: headache and abdominal discomfort.
• Serious effects: OHSS and allergic reactions.

Serious symptoms such as difficulty breathing, rash, significant abdominal pain, nausea, vomiting, or rapid weight gain need urgent medical attention.

What to check in the official leaflet or SPC

If you are reviewing Ovitrelle for treatment planning or medicines information, it is sensible to confirm the following in the official leaflet or SPC:

• The exact strength and presentation.
• How the pen should be prepared and injected.
• Warnings and precautions relevant to your situation.
• Possible side effects and when to seek help.
• Any updates to the product information.

At a glance

Frequently asked questions

Where to find more information

For the most reliable information, use official sources such as the product SPC, the patient leaflet, or advice from the prescribing fertility clinic. These sources are the best place to confirm the current instructions and safety information.

General medical forums and informal online discussions may be helpful for support, but they should not replace official product information or professional advice.